Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • AbstractBACKGROUNDTreatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial.METHODSOverall, 1130 patients with breast carcinoma who had all types of bone metastases (osteolytic, mixed, or osteoblastic by radiology) were randomized to receive treatment with either 4 mg of Zol or 8 mg of Zol as a 15‐minute infusion or 90 mg of Pam as a 2‐hour infusion every 3–4 weeks for 12 months. A skeletal‐related event (SRE) was defined as a pathologic fracture, spinal cord compression, radiotherapy, or surgery to bone.RESULTSAmong all patients with BC, the proportion of those who had an SRE (primary endpoint) was comparable between treatment groups (43% of patients who received 4 mg of Zol vs. 45% of patients who received Pam). Among patients who had breast carcinoma with at least 1 osteolytic lesion (n = 528 patients), the proportion with an SRE was lower in the 4‐mg Zol group compared with the Pam group (48% vs. 58%), but this did not reach statistical significance (P = 0.058). The time to first SRE was significantly longer in the 4‐mg Zol group compared with the Pam group (median, 310 vs. 174 days; P = 0.013). Moreover, multiple‐event analysis demonstrated significant further reductions in the risk of developing SREs over the reduction achieved with Pam (30% in the osteolytic subset [P = 0.010] and 20% for all patients with BC [P = 0.037]).CONCLUSIONSThe current data indicate that treatment with 4 mg of Zol was more effective than 90 mg of Pam in reducing skeletal complications in a subset of patients with breast carcinoma who had at least 1 osteolytic lesion at study entry. Cancer 2004;100:36–43. © 2003 American Cancer Society.

authors

  • Rosen, Lee S
  • Gordon, David H
  • Dugan, William
  • Major, Pierre
  • Eisenberg, Peter D
  • Provencher, Louise
  • Kaminski, Mary
  • Simeone, Joe
  • Seaman, John
  • Chen, Bee‐Lian
  • Coleman, Robert E

publication date

  • January 2004

has subject area

published in